Gilead Sciences Inc
NASDAQ: GILD
$111.44
-$1.11 (-1.0%)
Closing Price on March 14, 2025
GILD Articles
The short interest data are out for the October 30 settlement date, and short interest fell in selected biotech stocks.
Published:
Last Updated:
24/7 Wall St. has collected several big FDA decisions coming up in the month of November.
Published:
Last Updated:
Gilead Sciences reported its third-quarter financial results after the markets closed on Tuesday.
Published:
Last Updated:
Gilead Sciences is set to report its third-quarter financial results after the markets close on Thursday.
Published:
The October 15 short interest data have been compared with the previous figures, and short interest mixed in these selected biotech stocks.
Published:
These biotech stocks 24/7 Wall St. has picked stood out from the rest with at least 25% gains over the course of the past week.
Published:
ThinkstockThe U.S. Food and Drug Administration (FDA) issued a warning that hepatitis C treatments, Viekira Pak and Technivie, can cause serious liver injury mostly in patients with underlying...
Published:
Last Updated:
Cowen says the way to play biotech is with large cap sector leaders that can beat earnings estimates. It also thinks third-quarter earnings beats could highlight the risk of not owning biotech now.
Published:
Tuesday's top analyst upgrades, downgrades and initiations include Bluebird Bio, Boston Beer, Etsy, Gilead Sciences, Pfizer, PMC-Sierra and Valeant Pharmaceuticals.
Published:
Last Updated:
The September 30 short interest data have been compared with the previous figures, and short interest increased in most of these selected biotech stocks for this settlement date.
Published:
Given the massive beat-down in the sector, if these companies surpass earnings expectations, the upside could be sizable.
Published:
Wikimedia CommonsIf there was ever a time when investors are thrilled to see the calendar change it could be now. With the fourth quarter just starting, many are more than relieved to put the third...
Published:
Friday’s top analyst upgrades, downgrades and initiations include AIG, Facebook, Gilead Sciences, Google, Regeneron Pharmaceuticals, Twitter, Valeant Pharmaceuticals and Vertex Pharmaceuticals.
Published:
24/7 Wall St. has taken a look at some of the largest biotech companies and highlighted the damage that a single tweet did to them last week.
Published:
The September 15 short interest data have been compared with the previous figures, and short interest in these selected stocks increased across the board for this settlement date.
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.